A Phase 2/3 interventional study of elismetrep in acute migraine treatment

Recruiting Phase 3 NCT07645924

Study Description

A study comparing elismetrep (K-304) to placebo for treating migraine attacks

Study Details

Registry ID:
NCT07645924
Conditions:
Migraine
Phase:
Phase 3
Target Enrollment:
1,800 participants
Start Date:
Age Range:
18–75 years
Healthy Volunteers:
No

Study Locations (120 sites)

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →